Prostate cancer smart screening, precision diagnosis, personalised treatment'
|
|
- Doris Williamson
- 6 years ago
- Views:
Transcription
1 Prostate cancer smart screening, precision diagnosis, personalised treatment' Prof. Hashim Ahmed PhD, FRCS(Urol), BM, BCh (Oxon), BA(Hons) Consultant Urological Surgeon Bupa Cromwell Hospital Clinics: Tuesday & Wednesday AM
2 The Prostate Cancer Diagnostic & Therapy Pathway is CONTROVERSIAL and POLARISED
3 Total Number of Cases Diagnosed Prostate cancer is a growing 100,000 health burden 50, Time, years
4 The errors that result from the current pathway... Clinically indolent cancers are identified by chance Clinically significant lesions are missed Important cancers are incorrectly classified as unimportant Men undergo whole-gland treatment which carries harm
5 A strategy to overcome the errors in the current pathway Not all lesions have the potential to progress to invasive and metastatic cancer Novel imaging and precision biopsy can identify those lesions that are likely to progress Tissue preservation (active surveillance and focal therapy) can reduce treatment related harms
6 The impact of screening with PSA is small with significant over-diagnosis, over-detection and over-treatment and pathway-related harms
7 7
8 ` 5/1000 men over 14 years have PCa death averted 120/1000 men over 14 years have PCa diagnosis 8
9
10
11 Endorsed by the British Association of Urological Nurses (BAUN), the British Association of Urological Surgeons (BAUS) and the Primary Care Urology Society (PCUS)
12 Risk factors for referral 1. Elevated PSA >/=3ng/ml on two readings 2. Normal PSA but abnormal free/total PSA ratio (defined by each lab but usually <25%) 3. High PSA density >/=0.15ng/ml/ml if a transrectal ultrasound volume has been calculated 4. First degree relatives (>/=2) with prostate cancer 5. Ethnic risk e.g., African and African-Caribbean men
13 Can we diagnose prostate cancer better?
14 Template Mapping Biopsies Barzell and Melamed, 2007 Kepner and Kepner, 2010
15
16 Multi-parametric MRI: We can rule-out clinically significant disease accurately (but it s not 100%)
17
18
19
20 2 cores, Gleason 4+3, 2mm 1 core, Gleason 3+3,1mm
21 There was a palpable lack of level 1 evidence til now
22 PROMIS: Prostate MRI Imaging Study Presenter & Co-CI: Mr Hashim Ahmed Chief Investigator: Prof Mark Emberton Sponsored by University College London Managed by MRC Clinical Trials Unit Funded by UK NIHR HTA PROMIS is funded by the UK Government Department of Health, National Institute of Health Research Health Technology Assessment Programme, (Project number 09/22/67). UK Department of Health Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the health technology assessment program, NIHR, NHS or the Department of Health.
23 Trial Design
24 Level 1b diagnostic study Validating paired-cohort confirmatory study Eligible, consenting patients with clinical suspicion of prostate cancer Visit 1: Registration Visit 2: MP-MRI (1.5 Tesla) Visit 3: Combined biopsy (under general anaesthetic) 1st: TPM-biopsy 2nd: TRUS-biopsy Visit 4: End of study Results given to patients El-Shater Bosaily A et al; PROMIS Group. Contemp Clin Trials. 2015;42:26-40.
25 Reference Test Template Prostate Mapping (TPM) Excellent diagnostic accuracy Prostate biopsies every 5mm Requires general anaesthetic Barzell WE, Melamed MR. Urology. 2007;70(6 Suppl) Crawford ED et al. Prostate. 2013;73(7):
26 Blinding MP-MRI Report blinded to patients and physicians Radiologists not present at time of biopsy Biopsy Pathologists blinded to MP-MRI TPM-biopsy and TRUS-biopsy sent to different expert uropathologists
27 Results
28 MP-MRI compared to TRUS-biopsy Test attribute TRUSbiopsy MP-MRI Odds ratio* [95% CI] p-value Sensitivity 48% 93% 0.06 [ ] Specificity 96% 41% 0.02 [ ] PPV 90% 51% 8.2 [ ] NPV 74% 89% 0.34 [ ] p< p< p< p< McNemar test to compare sensitivity and specificity; GEE logistic regression model to compare PPV and NPV
29 If MP-MRI were used as a triage test, what types of clinically significant cancers would be missed?
30 % by status of disease MP-MRI scores and disease severity Significant cancer Insignificant cancer No cancer N=23 N=135 N=163 N=120 N=135 MP-MRI score
31 Clinically significant cancers missed by TRUS-biopsy and MP-MRI Number and cancer core length (mm) Gleason 3+3 Gleason 3+4 Gleason >/=4+3 TRUSbiopsy Total = (6-11mm) 99 (6-14mm) 13 (3-16mm) MP-MRI Total = 17 1 (8mm) 16 (6-12mm) 0
32 Do we need systematic biopsies in addition to MR targeted biopsies? 32
33 Systematic TRUS biopsies detected 6.7% more tumours than targeted alone
34 MRI negative cases harboured only Gleason 6 cancer on systematic TRUS biopsy 34
35 If one is really serious about overcoming the 1 in 10 miss rate of MP-MRI for clinically significant prostate cancer, then you should not be applying a systematic TRUS biopsy that has a 1 in 3 miss rate You should do a template mapping biopsy 35
36 A recent update UCL series Total cores taken v Cores positive for any cancer men undergoing visual-estimated targeted transperineal biopsies and Template Mapping Biopsies Template Biopsy Targeted Biopsy
37 Balance between under-detection and overdiagnosis Significant Cancer Insignificant Cancer No Cancer Template Biopsy Biopsy Targeted Targeted Biopsy Biopsies
38 However, transperineal GA Mapping biopsies in all is an unsustainable strategy Would cost an additional 250M / year in the UK Impact on healthcare systems would be disastrous Such a strategy is clearly NOT the way forward 38
39 Can MRI targeted biopsies detect clinically significant cancer? 39
40
41
42
43
44 MRI-Targeted biopsy compared to TRUS Biopsy was better for clinically significant tumour SEN 0.91 vs MRI-targeted biopsy detected fewer insignificant prostate cancer SEN 0.44 vs. 0.83
45 Bupa London Prostate Diagnostic Pathway
46 The current pathway (predominantly private units South-East England) Elevated PSA or suspicious rectal exam First consultation Tests organised - Urine culture - Repeat PSA - Prostate volume ultrasound measurement Second consult MRI Third consult Prostate Biopsy Transperineal GA Biopsy or TRUS biopsy Results consult
47 The current pathway If 100 men were going through this typical pathway for private prostate cancer evaluation, there would be 400 face to face consultations, 100 MRI scans, and 100 biopsy procedures In London: Biopsies usually transperineal general anaesthetic with histology pots OR Transrectal biopsies (sepsis risk of 2-4%).
48 The Bupa Prostate Pathway Streamlined, high quality, consultant-led, evidencebased.
49 Repeat PSA +/- MSU if dipstick positive Consult with urologist (teleconsult or face-to-face) Multi-parametric MRI (Cromwell Hospital) Consult with urologist (face-to-face) MRI not suspicious MRI suspicious PSA monitoring Transperineal sedation/la image-fusion biopsies (Cromwell)
50 The Bupa London Pathway If 100 men entered this pathway, there would be 100 teleconsults, 200 face-to-face consults, 100 MRI scans, and 75 biopsy procedures Biopsies under local anaesthetic/sedation with 2-3 histology pots and transperineal (sepsis 1 in 500)
51 So, we can detect prostate cancer better Can we reduce the harms of treatment once they are diagnosed?
52 Treatment options for localised prostate cancer Certainty of Cancer Control No to low risk of Side-effects Radical Treatments Prostate Cancer Active Surveillance Problems Incontinence (5-20%) Impotence (30-60%) Rectal toxicity (5-10%) Cost Over-treatment Problems Cancer Progression Psychological Burden Surveillance Burden Surveillance Cost
53 break our cultural addiction to immediate treatment for all and move toward discriminating, selective, and more socially responsible behavior in this challenging disease
54
55 Treatment of localised prostate cancer may have some survival benefit (if clinically significant)
56 Scandinavian Trial Watchful waiting vs. Surgery
57 USA Trial Watchful waiting vs. Surgery
58 UK PROTECT Trial
59 Treatment-related harms are significant Side-effects in the average centre
60
61
62 Treatment-related harms are significant Side-effects in the best centres
63 63
64 Radical surgery Radical Radiotherapy Incontinence 10-20% 10-20% Impotence 30-60% 50-60% Rectal toxicity 1% 5% Failure at 5 years 5-10% 5-10%
65 Active surveillance
66 Active surveillance Low risk disease (Gleason 6, PSA <10, localised) Some intermediate risk cancers (Gleason 3+4) Other criteria - MRI shows no or small lesion - Biopsy low risk disease is concordant with MRI - Co-morbidity - Starting a family (short period of surveillance) - Patient choice
67 Life-style advice for prevention/reduced progression Aerobic exercise Foods to increase: - brassicas (cauliflower, broccoli, cabbage, Brussel sprouts) - cooked tomatoes - nuts - green tea - pomegranate juice Meds:?aspirin?5-alpha reductase inhibitors
68 Will imaging help me manage my patients on active surveillance? 68
69 71 years old Active surveillance for low risk prostate cancer Gleason 3+3 maximum core length 2mm confirmed on template guided prostate biopsies November Presenting PSA subsequently running between and 7 until February April 2014 PSA 9.6. Current PSA 11 69
70 70
71 Scan two years later 71
72 72
73 73
74 74
75 Repeat Targeted transperineal Local Anaesthetic Biopsies Gleason 3+4 2mm 75
76 64 years old Active surveillance for Gleason 3+3, 2mm on biopsy (49 cores) 2010 Presenting PSA around 7 rising to a peak of 12, sixmonth post-biopsy falling to 9 in May
77 77
78 Repeat scan every 2 years 4 years later 78
79 79
80 Imaging can aid surgeons during radical prostatectomy
81 81
82 Focal therapy in prostate cancer The male lumpectomy
83 Focal Therapy Treating the cancer not the whole organ
84 The question is not new in the cancer field Breast cancer Thyroid cancer Kidney Liver Lumpectomy Hemithyroidectomy Partial nephrectomy Partial resection In fact, almost all other nonhaemaotological cancers
85 Focal Cryotherapy
86 y PSA 8.9 DRE N PSA 16 PSA 18 PSA 25 Negative TRUS TRUS: Gl 3+3 1mm TRUS: Focal HPIN 86
87 DCE 87
88
89 3 weeks post 89
90 That which the scalpel fails to cure, heat can cure. If the heat cannot cure, it must be deemed incurable William Osler
91
92
93 Radical surgery Radical Radiotherapy Focal therapy Incontinence 10-20% 10-20% 1-2% Impotence 30-60% 50-60% 5-10% Rectal toxicity 1% 5% 0.1% Failure at 5 years 5-10% 5-10% 5-10%
94 Failure-free survival (need for radical and/or systemic therapy)
95 Metastases and/or cancer-specific survival At 5 years, - Metastasis-free survival 97% - Cancer-specific survival 100% - Overall survival 99% Number at risk Time since Focal HIFU (years)
96 Conclusions
97 Prostate cancer is the last (solid organ) cancer in which imaging is not a key element of the diagnostic pathway Multi-parametric MRI is likely to become a key component of the prostate cancer diagnosis pathway
98 Prediction Two Prostate cancer is the last cancer in which the biopsy process is based on chance Targeted biopsies to an MRI lesion are improving detection of significant cancers and reducing over-diagnosis of low risk disease
99 Prediction Four Prostate cancer is the last cancer in which we insist upon treating the whole organ harbouring the cancer Tissue preservation, both active surveillance and focal therapy, will reduce the over-treatment burden of localised disease
100 Thank you! How to refer? Call
Best Practice Pathway for Prostate Cancer
Best Practice Pathway for Prostate Cancer Hashim Ahmed Professor and Chair of Urology Consultant Urological Surgeon Division of Surgery, Imperial College London Department of Urology, Imperial College
More informationNational Cancer Communities of Practice Pathways Event. Thursday 8 February 2018 The Wesley Hotel, London
National Cancer Communities of Practice Pathways Event Thursday 8 February 2018 The Wesley Hotel, London Using MRI in the prostate cancer pathway a decade of experience Caroline Moore MD FRCS(Urol) Reader
More informationMRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know Michael S. Cookson, MD, FACS Professor and Chair Department of Urology Director of Prostate and Urologic Oncology University
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationProstate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
More informationOptimising Prostate Cancer Diagnostics
Specialist Urology Training Optimising Prostate Cancer Diagnostics 29-30 September 2015 Guy s Hospital London, UK www.guysandstthomasevents.co.uk 29-30 September 2015 Course details Dates 29 30 September
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationThe role of PSA in detection and management of prostate cancer
The role of PSA in detection and management of prostate cancer Kirby R. The role of PSA in detection and management of prostate cancer. Practitioner 2016; 260(1792):17-21 Professor Roger Kirby MA MD FRCS
More informationADVICE TO PATIENTS REQUESTING PSA MEASUREMENT FREQUENTLY-ASKED QUESTIONS
The British Association of Urological Surgeons 35-43 Lincoln s Inn Fields London WC2A 3PE Phone: Fax: Website: E-mail: +44 (0)20 7869 6950 +44 (0)20 7404 5048 www.baus.org.uk admin@baus.org.uk ADVICE TO
More informationNICE BULLETIN Diagnosis & treatment of prostate cancer
Diagnosis & treatment of prostate cancer NICE provided the content for this booklet which is independent of any company or product advertised Diagnosis and treatment of prostate cancer Introduction In
More informationThe Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon
Prostate case study Presented by Mr Alan Thompson Consultant Urological Surgeon 2 Part one Initial presentation A 62 year old male solicitor attends your GP surgery. He has rarely seen you over the last
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationProstate cancer timed clinical pathways
Prostate cancer timed clinical pathways December 2017 1 Context This document sets out preliminary best practice timed clinical pathways for prostate cancer. It is anticipated that Cancer Alliances will
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationProblems: TRUS Bx. Clinical questions in PCa. Objectives. Jelle Barentsz. Prostate MR Center of Excellence.
Multi-parametric MR imaging in Problems: TRUS Bx Low Risk Prostate Cancer Important cancers are missed Jelle Barentsz Clinically insignificant cancers are identified by Prostate MR Center of Excellence
More informationOne Stop Prostate Biopsy Protocol Author Consultation Date Approved
One Stop Prostate Biopsy Protocol Author Consultation Date Approved Urology Nurse Practioner PROTOCOL FOR MEN ATTENDING A ONE STOP PROSTATE BIOPSY CLINIC RATIONALE Prostate cancer is the most common cancer
More informationADVICE TO PATIENTS REQUESTING PSA MEASUREMENT
Frequently-Asked Questions What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication of prostate cancer, is available to you if you want
More informationMagnetic Resonance Imaging Targeted Biopsy of the Prostate
Magnetic Resonance Imaging Targeted Biopsy of the Prostate Policy Number: 7.01.152 Last Review: 3/2018 Origination: 3/2017 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationHow to detect and investigate Prostate Cancer before TRT
How to detect and investigate Prostate Cancer before TRT Frans M.J. Debruyne Professor of Urology Andros Men s Health Institutes, The Netherlands Bruges, 25-26 September 2014 PRISM Recommendations for
More informationMr Jeremy Grummet, Urological Surgeon MBBS, MS, FRACS Foundation 49 Men s Health Symposium August 2015
www.drjeremygrummet.com.au www.aua.com.au Mr Jeremy Grummet, Urological Surgeon MBBS, MS, FRACS Foundation 49 Men s Health Symposium August 2015 The dilemma Most men die with prostate cancer rather than
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationMedical Policy POLICY POLICY GUIDELINES BENEFIT APPLICATION BACKGROUND. MP Magnetic Resonance Imaging Targeted Biopsy of the Prostate
Medical Policy MP 7.01.152 Last Review: 8/30/2017 Effective Date: 11/15/2017 Related Policies: 7.01.121 Saturation Biopsy for Diagnosis and Staging of Prostate Cancer 8.01.61 Focal Treatments for Prostate
More informationTRUS Biopsy. Richard Hindley
TRUS Biopsy Richard Hindley TRUS Biopsy Random Blind to Location of Disease Poor repeatability Miss disease Over sample clinically insignificant disease Geometric evaluation of systematic transrectal ultrasound
More informationDiagnosis and management of prostate cancer in the
Diagnosis and management of prostate cancer in the Jeremy Teoh ( 張源津 ) Assistant Professor, Department of Surgery, The Chinese University of Hong Kong. Email: jeremyteoh@surgery.cuhk.edu.hk Estimated age-standardised
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationTransformation of the South West Prostate Cancer Diagnostic Pathway. 14 th May 2018
Transformation of the South West Prostate Cancer Diagnostic Pathway 14 th May 2018 Introduction by Mr Jonathon Miller Introduction National context Achieving World Class Cancer Outcomes: A Strategy for
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationPoor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA
https://doi.org/10.1007/s00345-018-2252-4 TOPIC PAPER Poor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA Stig Müller 1,2 Gunder Lilleaasen 1 Tor Erik
More informationPSA testing in New Zealand general practice
PSA testing in New Zealand general practice Ross Lawrenson, Charis Brown, Fraser Hodgson. On behalf of the Midland Prostate Cancer Study Group Academic Steering Goup: Zuzana Obertova, Helen Conaglen, John
More informationOFFICIAL. Document Status. NHS England INFORMATION READER BOX
NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning Nursing Trans. & Corp. Ops. Strategy & Innovation Finance Publications Gateway Reference: 07925
More informationPSA test. PSA testing is not usually recommended for asymptomatic men with < 10 years life expectancy Before having a PSA test men should not have:
PSA Debate PSA1 PSA2 PSA test PSA testing is not usually recommended for asymptomatic men with < 10 years life expectancy Before having a PSA test men should not have: had a DRE in the previous week. an
More informationClinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline Very Low-/Low-Risk Disease Jeffrey A. Cadeddu, MD Professor, Department of Urology UT Southwestern Medical Center Vice-Chair, AUA/ASTRO/SUO
More informationNavigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News
Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools
More informationLocalized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA
Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-
More informationScreening and Diagnosis Prostate Cancer
Screening and Diagnosis Prostate Cancer Daniel Heng MD MPH FRCPC Chair, Genitourinary Tumor Group Tom Baker Cancer Center University of Calgary, Canada @DrDanielHeng Outline Screening Evidence Recommendations
More informationProstate Cancer MRI. Accurate Diagnosis and Treatment. PSA to Prostate MRI. for patients and curious doctors
6 Prostate Cancer MRI Accurate Diagnosis and Treatment PSA to Prostate MRI for patients and curious doctors Samuel Aronson, M.D. Vincent Pelsser, M.D. Franck Bladou, M.D. Armen Aprikian, M.D. & Marc Emberton,
More informationTechnology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546
Padeliporfin for untreated localised prostate cancer Technology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546 NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationProstate Cancer: Diagnosis and management
National Institute for Health and Care Excellence Guideline version (Draft) Prostate Cancer: Diagnosis and management [D] Evidence reviews for diagnosing and identifying clinically significant prostate
More informationAnatomic Imaging of Prostate Cancer
Masoom Haider, MD, FRCP(C) Professor of Radiology, University of Toronto Clinician Scientist, Ontario Institute of Cancer Research Senior Scientist, Sunnybrook Research Institute Chief, Dept of Medical
More informationProstate Cancer Case Study 1. Medical Student Case-Based Learning
Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationMR-US Fusion. Image-guided prostate biopsy. Richard E Fan Department of Urology Stanford University
MR-US Fusion Image-guided prostate biopsy Richard E Fan Department of Urology Stanford University Who am I? An instructor in the Department of Urology Quick plug for MED 275B Intro to Biodesign for Undergraduates
More informationScreening for Prostate Cancer
Screening for Prostate Cancer Review against programme appraisal criteria for the UK National Screening Committee (UK NSC) Version 1: This document summarises the work of ScHARR 1 2 and places it against
More informationIt is time to abandon transrectal prostate biopsy for perineal biopsy. Con Argument
It is time to abandon transrectal prostate biopsy for perineal biopsy Con Argument Erik P. Castle M.D., F.A.C.S. Professor of Urology Mayo Clinic Department of Urology Phoenix, AZ None Financial Disclosures
More informationThe Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy
Original Article World J Nephrol Urol. 2018;7(1):12-16 The Impact of MRI-TRUS Cognitively Targeted Biopsy on the Incidence of Pathologic Upgrading After Radical Prostatectomy Ragheed Saoud a, Albert El-Haj
More informationThe 4Kscore A Precision Test for Risk of Aggressive Prostate Cancer. Reduce Unnecessary Invasive Procedures And Healthcare Costs
The 4Kscore A Precision Test for Risk of Aggressive Prostate Cancer Reduce Unnecessary Invasive Procedures And Healthcare Costs PSA Lacks Specificity for Aggressive Prostate Cancer Abnormal PSA leads to
More informationPROSTATE CANCER STRATIFIED FOLLOW UP. Hilary Baker Lead CNS for Uro-oncology MSc, BSc, RGN.
PROSTATE CANCER STRATIFIED FOLLOW UP Hilary Baker Lead CNS for Uro-oncology MSc, BSc, RGN. LEARNING OBJECTIVES To refresh your knowledge about prostate cancer. To discuss the purpose and patient benefits
More informationHorizon Scanning Technology Briefing. Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer
Horizon Scanning Technology Briefing National Horizon Scanning Centre Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer December 2006 This technology summary is based on
More informationTHE PROSTATE. SMALL GLAND BIG PROBLEM By John Crow. Chapter 4
THE PROSTATE SMALL GLAND BIG PROBLEM By John Crow Chapter 4 In this chapter I want to address the big issue CANCER. What is CANCER? As you will already know, our body tissue is made up of literally Billions
More informationcredible science. incredible therapeutics.
credible science. incredible therapeutics. Corporate Presentation NASDAQ: SPHS A p r i l 2019 2 Forward-Looking Statement Certain information contained in this presentation may constitute forward-looking
More information11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.
Multi-parametric MRI of Prostate Diagnosis and Treatment Planning Temel Tirkes, M.D. Associate Professor of Radiology Director, Genitourinary Radiology Indiana University School of Medicine Department
More informationProstate Cancer Screening Where are we? Prof. Bob Steele Professor of Surgery, University of Dundee Independent Chair, UK NSC
Prostate Cancer Screening Where are we? Prof. Bob Steele Professor of Surgery, University of Dundee Independent Chair, UK NSC 1990 Screening The detection of disease in asymptomatic people in order to
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Diagnosis and monitoring of prostate cancer: PROGENSA PCA3 assay and the Prostate Health Index (PHI) This overview summarises the key issues for the Diagnostics
More informationPeninsula Cancer Alliance Update Nov 2018 UROLGY SSG
Peninsula Cancer Alliance Update Nov 2018 UROLGY SSG National Support Funding NHS England has allocated National Support Funding (NSF) to the Peninsula Cancer Alliance (PCA) for 2018/19 a proportion of
More informationMRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review
MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review Poster No.: C-1208 Congress: ECR 2014 Type: Educational Exhibit Authors: J. Murphy, M.
More information4Kscore. A Precision Test for Risk of Aggressive Prostate Cancer
4Kscore A Precision Test for Risk of Aggressive Prostate Cancer How to Evaluate Risk for Prostate Cancer? PSA is a good screening tool But abnormal PSA leads to over 1 million prostate biopsies each year
More informationProstate Cancer Treatment Experts
Prostate Cancer Treatment Experts Category Offering HIFU A Cutting-Edge, Non-Invasive Treatment with Low Risk of Side Effects While prostate cancer is a fairly common disease among men in the US, with
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationMulti-parametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis For peer review only
Multi-parametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis Journal: Manuscript ID: bmjopen-0-00 Article Type: Research Date Submitted
More informationProstate MRI: Screening, Biopsy, Staging, and Ablation
Prostate MRI: Screening, Biopsy, Staging, and Ablation Scott Eggener, M.D. Associate Professor of Surgery- Urologic Oncology Director- Prostate Cancer Program University of Chicago International Prostate
More informationMR-TRUS Fusion Biopsy
MR-TRUS Fusion Biopsy Silvan Boxler Department of Urology Prostate cancer mortality according to risk groups Prevention of overdiagnosis and overtreatment Rider J, Eur Urol 2013 MR-TRUS Fusion Biopsy /
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationA biopsy can be avoided in patients with positive DRE and negative MRI. Disagree: Michael Cohen, Chairman, Dept. of Urol. Haemek M.
A biopsy can be avoided in patients with positive DRE and negative MRI Disagree: Michael Cohen, Chairman, Dept. of Urol. Haemek M.C, Afula, Israel Financial and Other Disclosures Off-label use of drugs,
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2018 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationcredible science. incredible therapeutics.
credible science. incredible therapeutics. Corporate Presentation NASDAQ: SPHS O c t o b e r 2018 2 Forward-Looking Statement Certain information contained in this presentation may constitute forward-looking
More informationAppendix 4 Urology Care Pathways
Appendix 4 Urology Care Pathways Cancer Care Pathways outline the steps and stages in the patient journey from referral through to diagnostics, staging, treatment, follow up, rehabilitation and if applicable
More informationThe SPARED CRN meeting
The SPARED CRN meeting FDA, Washington 5/3/2018 To Develop and Regulate Modern PCa-Care: a Secured, Integrated, Transversal Vision from Europe. Pr Roland van Velthoven, MD, PhD Dr Antoine Leroy, PhD Koelis
More informationProstatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London
Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of
More informationGetting to Diagnosis. Debbie Victor Uro-Oncology CNS Royal Cornwall Hospitals Trust
Getting to Diagnosis Debbie Victor Uro-Oncology CNS Royal Cornwall Hospitals Trust GP Visit Symptoms Reduced urinary flow Difficulty starting/stopping Urgency Frequency Nocturia Because a friend/relative
More informationMini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano
Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it
More information3/6/2018 PROSTATE CANCER IN 2018 OBJECTIVE WHAT IS THE PROSTATE? WHAT DOES IT DO? Rahul Mehan, MD
PROSTATE CANCER IN 2018 Rahul Mehan, MD East Valley Urology Center 6116 E Arbor Ave, Bldg 2, Suite 108 Mesa, AZ 85206 rmehan@evucenter.com www.evucenter.com Snapchat: Dr.NoodleKing OBJECTIVE Offer interactive
More informationEffective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18
PROVIDENCE HEALTH PLANS MEDICAL (HIFU) (All Lines of Business Except Medicare) Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18 11/1/18 Medical Officer
More information18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan
An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Jeremy Millar Director Radiation Oncology, Alfred Health Clinical lead Prostate Cancer Outcomes Registry, Monash University
More informationAllinaHealthSystems 1
2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationPSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016
PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence
More informationGuideline Prostate cancer: diagnosis and management (update)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline Prostate cancer: diagnosis and management (update) Draft for consultation, December 0 This guideline covers diagnosing and managing prostate
More informationIndex Lesion Only. Prof. Phillip D Stricker
Index Lesion Only Prof. Phillip D Stricker Financial and Other Disclosures Off-label use of drugs, devices, or other agents: None Data from IRB-approved human research is presented I have the following
More informationDiagnosis and Classification of Prostate Cancer
Patient Information English 32 Diagnosis and Classification of Prostate Cancer The underlined terms are listed in the glossary. prostate biopsy is the only test that can confirm a prostate cancer diagnosis.
More informationSaturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer
Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationMr Declan Cahill Consultant Urological Surgeon The Royal Marsden
Diagnosing prostate cancer Mr Declan Cahill Consultant Urological Surgeon 2 Marsden GP Education Day 22 February 2016 Should I have a PSA test? Can I have a PSA test? prostatecanceruk.org 4 83% raised
More informationManaging Prostate Cancer in General Practice
Managing Prostate Cancer in General Practice Tuesday 18 th September 2018 Presenters: Prof Jon Emery Assoc Prof Declan Murphy The education has been developed in partnership with Cancer Council Victoria,
More informationUrological Society of Australia and New Zealand PSA Testing Policy 2009
Executive summary Urological Society of Australia and New Zealand PSA Testing Policy 2009 1. Prostate cancer is a major health problem and is the second leading cause of male cancer deaths in Australia
More informationWhat Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen).
What Is Prostate Cancer? Prostate cancer is the development of cancer cells in the prostate gland (a gland that produces fluid for semen). It is a very common cancer in men; some cancers grow very slowly,
More informationProstate Cancer. David Wilkinson MD Gulfshore Urology
Prostate Cancer David Wilkinson MD Gulfshore Urology What is the Prostate? Male Sexual Gland Adds nutrients and fluids for sperm This fluid is added to sperm during ejaculation Urethra (urine channel)
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2019 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationResults. Conclusion. Keywords
Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable magnetic resonance-ultrasound (MR-US) registration system Louise Dickinson*, Yipeng Hu, Hashim
More informationThe diagnosis of prostate cancer comes with challenges.
1 The diagnosis of prostate cancer comes with challenges. The PSA test lacks the specificity to reliably detect prostate cancer and under our current guidance 1 requires asymptomatic men aged 50 and over
More informationIntroduction. American Society of Clinical Oncology All rights reserved.
Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement This is an endorsement
More informationTOOKAD (padeliporfin) Patient Information Guide
TOOKAD (padeliporfin) Patient Information Guide TOOKAD is used to treat low-risk localized prostate cancer This medicine is subject to additional monitoring. This will allow quick identification of new
More informationDavid Gillatt Bristol Urological Institute. David Gillatt Bristol UK
David Gillatt Bristol Urological Institute David Gillatt Bristol UK Prostate Problems The prostate grows with age - >80% men over 60 have benign enlargement As it grows it can obstruct the flow of urine
More informationMEDICAL POLICY SUBJECT: MAGNETIC RESONANCE IMAGING PROSTATE/MULTIPARAMETRIC MRI EFFECTIVE DATE: 06/21/18
MEDICAL POLICY SUBJECT: MAGNETIC RESONANCE IMAGING PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationProstate cancer: diagnosis and treatment
Prostate cancer: diagnosis and treatment Issued: January 2014 NICE clinical guideline 175 guidance.nice.org.uk/cg175 NICE has accredited the process used by the Centre for Clinical Practice at NICE to
More informationProstate Cancer Screening. A Decision Guide
Prostate Cancer Screening A Decision Guide This booklet was developed by the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). Is screening right for you?
More informationYour Guide to Prostate Cancer
Your Guide to Prostate Cancer If you face a diagnosis of prostate cancer, what s next? We can help. A prostate cancer diagnosis can be overwhelming. The good news is that while prostate cancer can be serious,
More information